

ASX RELEASE

30 August 2018

Results of Annual General Meeting

Innate Immunotherapeutics Limited (ASX Code: IIL) is pleased to confirm that each of the resolutions considered at its Annual General Meeting held earlier today were passed.

Results of the Annual General Meeting are summarised as follows:

#	RESOLUTION	PASSED/ FAILED	VOTE SoH*/ POLL	PROXIES FOR	PROXIES AGAINST	PROXIES DISCRETION	PROXIES ABSTAIN
2	Remuneration Report	Passed	SoH	8,227,304	3,053	286,497	16,570
3	Re-Elect Mr. Robert Peach as a Director	Passed	SoH	12,126,957	46,450	2,003,775	465
4	Approve Grant of Options to Mr. Robert Peach	Passed	SoH	10,450,687	58,785	1,947,775	2,972
5	Approve Grant of Options to Mr. Andrew Cooke	Passed	SoH	10,446,402	63,070	1,947,775	2,972
6	Approve Grant of Options to Mr. Simon Wilkinson	Passed	SoH	10,432,187	77,485	1,947,775	2,772
7	Approve Change of Name to Amplia Therapeutics Limited	Passed	SoH	12,209,733	16,354	1,947,875	3,685

For Further Information:

Mr Simon Wilkinson, CEO

+64 21 661 850

or visit the Innate Immunotherapeutics website at www.innateimmuno.com

-End-